<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15270">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00183469</url>
  </required_header>
  <id_info>
    <org_study_id>P20MH068662</org_study_id>
    <secondary_id>5P20MH068662</secondary_id>
    <secondary_id>DSIR 83-ATSO</secondary_id>
    <nct_id>NCT00183469</nct_id>
  </id_info>
  <brief_title>Maintenance Treatment of Bipolar Depression</brief_title>
  <official_title>Eight-Month Maintenance Treatment of Bipolar Depression With Lamotrigine or Lamotrigine Plus Divalproex Combination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare two different antidepressant treatment regimens to determine which
      is more effective in reducing symptoms of bipolar depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depression is a serious condition that is often difficult to diagnosis and treat. Bipolar
      disorder-related depression is especially complex because of the presence of mania symptoms.
      Lamotrigine and divalproex are commonly prescribed medications for depression. However,
      their effectiveness in treating bipolar depression has not been thoroughly evaluated.
      Studies have shown that combining lamotrigine with another antidepressant may be more
      effective in reducing depressive symptoms than lamotrigine alone. This study will provide
      participants with either lamotrigine alone or in combination with divalproex and will
      determine which regimen is more effective in reducing symptoms of bipolar depression.

      Participants will be randomly assigned to a daily regimen of either lamotrigine and
      divalproex or lamotrigine and placebo for 8 months. Participants will be assessed at study
      entry, at two unspecified times during the study, and at the end of the study. During each
      assessment, participants will undergo a brief interview and complete a questionnaire about
      their depressive symptoms, any physical manifestations of their depression, and their
      overall level of functioning in daily activities.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mania Rating Scale</measure>
    <time_frame>up to 8 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Severity of the illness and psychopathological features will be measured by the increase in the SADS Mania Rating Scale, with higher scores representing worse mania. The range of this scale is 0-75.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>lamotrigine plus divalproex ER</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will take active lamotrigine and active divalproex ER</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lamotrigine plus placebo divalproex ER</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will take active lamotrigine and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
    <description>If the participant is naive to LAM, LAM will be started at 25 mg every day for the first 2 weeks, then 50 mg per day for the next 2 weeks. The dose of LAM can be increased to 100 mg at week 5 and increased to maximum of 200 mg at week 6 based on symptoms, tolerability, and ratings of the rating scales. If the participant is already taking LAM, the dose will be increased to up to 200 mg using the same guide lines. Upon randomization the participant in the placebo comparator will have their dosage titrated to doubled since the potentiating effect of the Divalproex will no longer exist. It will remain at this dosage until the end of the study with the possibility of one adjustment for side effects.</description>
    <arm_group_label>lamotrigine plus divalproex ER</arm_group_label>
    <arm_group_label>lamotrigine plus placebo divalproex ER</arm_group_label>
    <other_name>Lamictal</other_name>
    <other_name>(LAM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Divalproex (DIV) ER</intervention_name>
    <description>If the participant is naive to DIV and if LAM was initiated before the start of treatment with DIV, DIV can be started at any point of time in the study provided the participant has been on LAM for at least 2 weeks. DIV will be started at 500 mg and titrated by increments of 500 mg every 3 to 4 days until a therapeutic blood level is attained up to 2500 mg.</description>
    <arm_group_label>lamotrigine plus divalproex ER</arm_group_label>
    <other_name>Depakote ER</other_name>
    <other_name>valproic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>During the randomized phase participants randomized to placebo comparator group will discontinue DIV and will start taking the placebo in the same fashion.</description>
    <arm_group_label>lamotrigine plus placebo divalproex ER</arm_group_label>
    <other_name>PBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of bipolar disorder I or II

          -  Experiencing symptoms of depression at study entry OR have experienced symptoms of
             depression within 6 months prior to study entry

          -  Willing to use acceptable methods of contraception

          -  Parent or guardian willing to provide informed consent, if applicable

        Exclusion Criteria:

          -  History of liver disease

          -  History of substance abuse

          -  Previous treatment with lamotrigine or divalproex

          -  Lamotrigine or divalproex intolerance
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles L. Bowden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>210-567-5405</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Bowden CL, Singh V, Weisler R, Thompson P, Chang X, Quinones M, Mintz J. Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo-controlled maintenance treatment for bipolar depression. Acta Psychiatr Scand. 2012 Nov;126(5):342-50. doi: 10.1111/j.1600-0447.2012.01890.x. Epub 2012 Jun 18.</citation>
    <PMID>22708645</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 15, 2015</lastchanged_date>
  <firstreceived_date>September 13, 2005</firstreceived_date>
  <firstreceived_results_date>April 10, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Charles L. Bowden</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Lamotrigine</keyword>
  <keyword>Divalproex</keyword>
  <keyword>Antidepressant</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anticonvulsants</mesh_term>
    <mesh_term>Lamotrigine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment from October 2004 to September 2007 took place in Univ of Texas Health Science Center San Antonio and Center for Healthcare services and television advertisements.</recruitment_details>
      <pre_assignment_details>1st 8 weeks is Open Label phase. Subjects are either in a depressed episode or have been depressed in last 6 mos. In this phase subjects will take lamotrigine and divalproex ER. Those who remained depressed, or developed an episode, during 2 consecutive visits, were terminated at, or by, week 8.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Double-Blind Lamotrigine and Divalproex ER</title>
          <description>Double blind randomized participants will take active lamotrigine and active divalproex Er</description>
        </group>
        <group group_id="P2">
          <title>Double-Blind Lamotrigine and Placebo Divalproex ER</title>
          <description>Double-Blind randomized Participants will take active lamotrigine and placebo divalproex ER</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lamotrigine Plus Divalproex ER</title>
          <description>Enrolled subjects received lamotrigine and divalproex ER</description>
        </group>
        <group group_id="B2">
          <title>Lamotrigine Plus Placebo Divalproex ER</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="41"/>
                <measurement group_id="B2" value="45"/>
                <measurement group_id="B3" value="86"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="41"/>
                <measurement group_id="B2" value="45"/>
                <measurement group_id="B3" value="86"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="37.6" spread="11.0"/>
                <measurement group_id="B2" value="42.1" spread="12.7"/>
                <measurement group_id="B3" value="39.9" spread="11.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="26"/>
                <measurement group_id="B3" value="47"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="39"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="41"/>
                <measurement group_id="B2" value="45"/>
                <measurement group_id="B3" value="86"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mania Rating Scale</title>
        <description>Severity of the illness and psychopathological features will be measured by the increase in the SADS Mania Rating Scale, with higher scores representing worse mania. The range of this scale is 0-75.</description>
        <time_frame>up to 8 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>all randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Double-Blind Lamotrigine and Divalproex ER</title>
            <description>Double blind randomized participants will take active lamotrigine and active divalproex Er</description>
          </group>
          <group group_id="O2">
            <title>Double-Blind Lamotrigine and Placebo Divalproex ER</title>
            <description>Double-Blind randomized Participants will take active lamotrigine and placebo divalproex ER</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="45"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mania Rating Scale</title>
            <description>Severity of the illness and psychopathological features will be measured by the increase in the SADS Mania Rating Scale, with higher scores representing worse mania. The range of this scale is 0-75.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.54" spread=".64"/>
                  <measurement group_id="O2" value="5.57" spread=".6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10/19/2004 - 6/12/2008, 3years 8 months</time_frame>
      <desc>subject reporting and systematic questionnaires</desc>
      <group_list>
        <group group_id="E1">
          <title>Lamotrigine Plus Active Divalproex ER</title>
          <description>randomized participants will take active lamotrigine and active divalproex Er</description>
        </group>
        <group group_id="E2">
          <title>Lamotrigine Plus Placebo Divalproex ER</title>
          <description>randomized subjects will take active lamotrigine and placebo divalproex ER</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charles L. Bowden, M.D. Clinical Professor</name_or_title>
      <organization>University of Texas Health Science Center San Antonio</organization>
      <phone>210 567 5405</phone>
      <email>bowdenc@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
